Trial · NCT00113360
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
NCT00113360, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2010-12-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma. Trials, record NCT00113360. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00113360
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
- NCT number
- NCT00113360
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 67 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Neuroendocrine Carcinoma, Islet Cell Carcinoma
- Interventions
- RAD001, Octreotide Depot
- First posted
- 2005-06-08
- Last updated
- 2026-07-06
- Results first posted
- 2010-12-07
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) | PFS assessed every 12 weeks (at the end of every 3 cycles) or more frequently if clinically indicated | PFS is measured from date of trial entry until documented progression of disease or death from any cause. PFS is measured by computed tomography (CT) scans or magnetic resonance imaging (MRI) performed at baseline and after every three cycles. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression Free Survival (PFS) | PFS assessed every 12 weeks (at the end of every 3 cycles) or more frequently if clinically indicated | Per protocol | Weeks | MEDIAN |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | RAD001 Plus Octreotide Depot | 60 | 95% Confidence Interval 54 to 66 | Weeks |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | RAD001 Plus Octreotide Depot | 67 | |
| Overall Study | COMPLETED | RAD001 Plus Octreotide Depot | 60 | |
| Overall Study | NOT COMPLETED | RAD001 Plus Octreotide Depot | 7 |
Source ClinicalTrials.gov
Adverse events44
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ALT, SGPT | Investigations | RAD001 Plus Octreotide Depot | 24 | 64 | 37 |
| other | AST,SGOT | Investigations | RAD001 Plus Octreotide Depot | 40 | 64 | 51 |
| other | Alkaline phosphatase | Investigations | RAD001 Plus Octreotide Depot | 6 | 64 | 6 |
| other | Anorexia | Gastrointestinal disorders | RAD001 Plus Octreotide Depot | 4 | 64 | 4 |
| other | Bilirubin | Investigations | RAD001 Plus Octreotide Depot | 4 | 64 | 7 |
| other | Calcium, serum-low (hypocalcemia) | Investigations | RAD001 Plus Octreotide Depot | 4 | 64 | 4 |
| other | Diarrhea | Gastrointestinal disorders | RAD001 Plus Octreotide Depot | 32 | 64 | 73 |
| other | Dry skin | Skin and subcutaneous tissue disorders | RAD001 Plus Octreotide Depot | 6 | 64 | 6 |
| other | Edema, limb | Blood and lymphatic system disorders | RAD001 Plus Octreotide Depot | 8 | 64 | 11 |
| other | Fatigue | General disorders | RAD001 Plus Octreotide Depot | 40 | 64 | 96 |
1 to 10 of 44Source ClinicalTrials.gov
See all 44 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | RAD001 Plus Octreotide Depot | ||
| Total, other adverse events | RAD001 Plus Octreotide Depot | 64 | 64 |
| Total, serious adverse events | RAD001 Plus Octreotide Depot | 3 | 64 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00113360
GET https://conductscience.org/api/trials/v1/NCT00113360/events?page=2